Company Overview - Xenon Pharmaceuticals is a clinical-stage biotechnology company focused on developing novel therapeutics for neurological conditions, particularly epilepsy [5][6] - The company has a robust pipeline of potassium and sodium channel modulators, with key drug candidates including XEN496, XEN1101, NBI-921352, and XEN007 [6][7] - As of the latest data, Xenon has a market capitalization of $4.9 billion and reported revenue of $7.50 million, with a net income of -$345.91 million [4] Recent Developments - On February 17, 2026, Driehaus Capital Management disclosed an increase in its position in Xenon Pharmaceuticals by 369,577 shares, valued at approximately $15.52 million [1][2] - The total value of Driehaus's position in Xenon rose by $36.03 million due to both the increased stake and market price changes [2] - Following strong Phase 3 trial results for its lead drug candidate, azetukalner, which showed a median seizure reduction of 53.2% in treated patients, Xenon plans to file for U.S. regulatory approval later this year [8][9] Market Performance - Xenon shares were priced at $58.33, reflecting a 66% increase over the past year, significantly outperforming the S&P 500's 19% gain during the same period [5][9] - The company's recent public offering of $747.5 million has strengthened its balance sheet, aiding in commercialization efforts and pipeline expansion [9] Investment Positioning - Driehaus Capital Management's stake in Xenon now represents 1.4% of its 13F reportable assets under management, positioning it alongside other neuroscience-focused investments [5][10] - The recent momentum in Xenon's stock performance suggests it may stand out among its peers in the biotechnology sector [10]

Core Viewpoint - Braidwell has reduced its stake in Xenon Pharmaceuticals by 1,779,953 shares, valued at approximately $74.76 million, reflecting a significant decline in the value of its investment due to both share sales and market price changes [1][2]. Company Overview - Xenon Pharmaceuticals is a biotechnology company focused on developing novel therapeutics for neurological disorders, utilizing a robust clinical pipeline and strategic partnerships to advance drug candidates toward regulatory approval [6]. - The company specializes in ion channel modulation, offering a differentiated approach to treating epilepsy and related conditions [6]. Financial Metrics - As of February 17, 2026, Xenon shares were priced at $41.66, with a market capitalization of $3.28 billion [4]. - The company reported a trailing twelve months (TTM) revenue of $7.50 million and a net income loss of $306.33 million [4]. Recent Developments - Braidwell's position in Xenon now constitutes approximately 2.62% of its 13F assets under management (AUM) after the sale [8]. - The stock has increased by approximately 6.4% over the past year but has underperformed the S&P 500 by about 4.85 percentage points [8]. Clinical Pipeline - Xenon is approaching a critical milestone with the Phase 3 X-TOLE2 topline data for azetukalner in focal onset seizures expected in March 2026, which could lead to a New Drug Application (NDA) submission in the second half of 2026 [10]. - The company has completed enrollment for the X-TOLE2 study with 380 patients and is conducting five additional Phase 3 studies across epilepsy and neuropsychiatry [12]. Investment Strategy - The reduction in Braidwell's position indicates a strategy to spread risk across multiple late-stage programs rather than concentrating on a single binary event [11].